Introduction
============

Benign prostatic hyperplasia (BPH) is a common and frequently encountered disease in middle-aged and old males ([@b1-etm-0-0-9102]). The incidence of BPH in males is \~40% at the age of 50 and \~90% after the age of 80 years ([@b2-etm-0-0-9102],[@b3-etm-0-0-9102]).

The transurethral resection of the prostate (TURP) is the gold standard of BPH surgical treatment in men with prostate size of 30-80 ml ([@b4-etm-0-0-9102]). In recent years, holmium laser, 2 µm laser and green laser have been widely used among clinicians for their excellent coagulation hemostasis and non-conductive properties. Two-micrometer laser is a high-energy laser with a wavelength of 2 µm, which is close to the maximum absorption peak of 1.94 µm of water. It can be absorbed by the water in the tissue and produce a thermal effect, effectively achieving the purpose of cutting and vaporizing the tissue, with little heat loss to the surgical area ([@b5-etm-0-0-9102]). However, intraoperative and postoperative bleeding is still the main complication of surgical treatment ([@b6-etm-0-0-9102]). With the aging of the population and the increase of the incidence of cardiovascular and cerebrovascular diseases, the number of BPH patients requiring surgical treatment while taking oral antithrombotic drugs is also increasing year by year, further increasing the risk of perioperative bleeding ([@b7-etm-0-0-9102]). However, recent studies have found that the type of antithrombotic agents is not a major factor in the risk of perioperative bleeding in patients with BPH ([@b8-etm-0-0-9102],[@b9-etm-0-0-9102]). Meskawi *et al* ([@b9-etm-0-0-9102]) treated BPH patients undergoing laser surgery with antiplatelet agents such as clopidogrel acetylsalicylate and anticoagulants such as warfarin, thrombin inhibitors and rivaroxaban. However, they found no significant difference in the effect of different antithrombotic drugs on the risk of bleeding. So the effect of antithrombotic drugs on bleeding risk may be related to other factors. A large number of studies considered that antithrombotic drugs will increase the risk of perioperative bleeding, and it is recommended to interrupt anticoagulation preoperatively ([@b10-etm-0-0-9102]). However, some studies have pointed out that the risk of cardiovascular and cerebrovascular events after stopping antithrombotic drugs is three times higher than that of the group that did not stop using antithrombotic drugs ([@b11-etm-0-0-9102]). Therefore, this study adopted the method of systematic review to evaluate the impact of continuous use of antithrombotic drugs on intraoperative and postoperative bleeding risk of BPH patients, aiming to provide theoretical basis for clinical treatment decisions.

Materials and methods
=====================

### Search strategy

We searched Pubmed, Embase and Cochrane library databases. The search terms were 'antithrombotic or aspirin or antiplatelet or heparin' and 'prostatic hyperplasia', and limited fields in the title and abstract. In order to increase the search efficiency, we also excluded the studies with keywords 'meta-analysis', 'review' and 'case report'. The time of publication was from inception to February 28, 2019. In addition, we searched the reference list of acquired articles manually.

### Inclusion and exclusion criteria

Inclusion criteria: i) Type of study: Clinical controlled trial. ii) Study subjects: prostate surgery patients (including electric resection and laser surgery). iii) Intervention measures: experimental group, perioperative continuous application of antithrombotic drugs (including antiplatelet drugs and anticoagulant drugs), continuous use of antithrombotic drugs was defined as the patients did not stop using antithrombotic drugs during the surgery. Control group, antithrombotic drugs were discontinued preoperatively or not. The discontinued antithrombotic drugs were defined as drugs were discontinued preoperatively for 5-10 days, and anticoagulants, including novel oral anticoagulants-NOACs, were not used in discontinued patients during discontinuation. The unused antithrombotic drugs were defined as drugs were never taken or discontinued preoperatively for more than 30 days. iv) At least one outcome index was reported: incidence of postoperative bleeding, blood transfusion rate, decreased intraoperative hemoglobin, catheterization duration and incidence of cardiovascular and cerebrovascular events.

Exclusion criteria: i) The studies were repeatedly published; ii) No control group was set up in the study; iii) Incomplete information or unable to obtain complete information of the study.

### Data extraction and quality assessment

Study screening and data extraction were performed independently by two reviewers. Firstly, the related studies were selected by browsing the title and abstract of the article. After excluding the studies that did not meet the inclusion criteria, the full text of the studies that might meet the inclusion criteria was searched and read, and then screened again. Two researchers cross-checked the included studies. For the studies with differences and difficult to reach consensus, the third researcher was asked to decide.

The extracted data included: i) basic information of the included studies, including author, publication time, country or region where the study was carried out, and sample size; ii) drugs and surgical methods; iii) anticoagulation mode and outcome indicators; iv) study quality evaluation of the relevant information.

Two researchers evaluated the quality of the included studies according to the Newcastle Ottawa scale (NOS) ([@b12-etm-0-0-9102]), and the third reviewer evaluated the studies when the scores were inconsistent. The full score of NOS score is 9, and the evaluation content includes the selection and exposure factors of the case control study, the comparability between groups, etc. The score of more than 6 is divided into high-quality study.

### Observed indicator

Antithrombotic agents and bleeding risk after transurethral therapy of benign prostatic hyperplasia were evaluated by the following observed indicator: Incidence of postoperative bleeding, blood transfusion rate, decreased intraoperative hemoglobin, catheterization duration and incidence of cardiovascular and cerebrovascular events.

### Statistical analysis

RevMan5.3 software was used to complete the meta-analysis process. Mean difference (MD) and 95% confidence interval (95% CI) was used for measurement data, odds ratio (OR) and 95% CI was used for categorical data, and P\<0.05 was considered statistically significant. The statistical heterogeneity among the studies was analyzed by Chi-square test, and the studies with good homogeneity (P\>0.05 and I^2^ \<50%) were analyzed with the fixed-effect model. If there is heterogeneity (P\<0.05 or I^2^ \>50%), the source of heterogeneity will be analyzed. If there is no obvious heterogeneity, the random effect model will be used for analysis. If there is heterogeneity, the stability and reliability of the results can be verified by subgroup analysis or sensitivity analysis.

Results
=======

### Study selection and study characteristics

A total of 20 studies ([@b13-etm-0-0-9102]) were included in this analysis and the study screening process is shown in [Fig. 1](#f1-etm-0-0-9102){ref-type="fig"}. Baseline data of included studies are shown in [Table I](#tI-etm-0-0-9102){ref-type="table"}. Among them, 8 studies ([@b13-etm-0-0-9102]) reported TURP and 5 studies ([@b22-etm-0-0-9102]) reported holmium laser enucleation of the prostate (HoLEP). Four studies ([@b27-etm-0-0-9102]) reported photoselective vaporization of the prostate (PVP). Thulium laser vaporesection of the prostate (ThuVARP) was used as surgical methods in 2 studies ([@b31-etm-0-0-9102],[@b32-etm-0-0-9102]) and 1 study ([@b21-etm-0-0-9102]) reported thulium laser enucleation of the prostate (ThuLEP). The quality assessment of the included studies is shown in [Table II](#tII-etm-0-0-9102){ref-type="table"}.

### TURP: Persistent-usage group vs. discontinued group

Three studies reported incidence of postoperative bleeding and incidence of cardiovascular and cerebrovascular events, and four studies reported blood transfusion rates. Compared with the discontinued group, the persistent-usage group has a high incidence of postoperative bleeding (OR=4.34, 95% CI=2.29-8.23) and blood transfusion rate (2.96, 1.19-7.36), while the difference in the incidence of cardiovascular and cerebrovascular events is not statistically significant (0.76, 0.14-4.18) ([Fig. 2](#f2-etm-0-0-9102){ref-type="fig"}).

### TURP: Persistent-usage group vs. not taking group

The incidence of postoperative bleeding was reported in four studies, with obvious heterogeneity among studies. The random effect model was performed, and the results showed that the incidence of postoperative bleeding was high in the persistent-usage group (5.52, 1.64-18.66). Three studies reported that transfusion rates were higher in the persistent-usage group than that in not taking group (4.97, 1.73-14.28) ([Fig. 3](#f3-etm-0-0-9102){ref-type="fig"}).

### Laser surgery: Persistent-usage group vs. discontinued group

Blood transfusion rates were reported in three studies, and were higher in the persistent-usage group than that in the discontinued group (5.39, 1.49-19.53). Three different studies reported decreased intraoperative hemoglobin, with no statistically significant difference between the groups (0.00, -0.03-0.03) ([Fig. 4](#f4-etm-0-0-9102){ref-type="fig"}).

### Laser surgery: Persistent-usage group vs. not taking group

Two studies reported blood transfusion rates and three reported catheterization duration. The results showed that there was no significant difference in blood transfusion rate (1.56, 0.18-13.59) and catheterization duration (0.15, -0.17-0.47) between the two groups ([Fig. 5](#f5-etm-0-0-9102){ref-type="fig"}).

### Laser surgery: Persistent-usage group vs. heparin group

Three studies reported blood transfusion rates, and two reported decreased intraoperative hemoglobin and catheterization duration. Compared with the heparin group, the persistent-usage group had a lower intraoperative decreased intraoperative hemoglobin (-0.46, -0.58\--0.35). There was no significant difference in blood transfusion rate (1.22, 0.36-4.14) and catheterization duration (-0.04, -0.33-0.25) ([Fig. 6](#f6-etm-0-0-9102){ref-type="fig"}).

Discussion
==========

In recent years, the number of patients requiring oral antithrombotic drugs due to cardiovascular and cerebrovascular diseases increased rapidly, and there was great controversy over the perioperative anticoagulation management of these patients, especially the intraoperative and postoperative bleeding ([@b33-etm-0-0-9102]). Due to the lack of high-quality RCT studies, urologists currently have no unified consensus on the management of antithrombotic drugs, relying only on long-term clinical experience or existing observational studies. Although American Urological Association and International Consultation on Urological diseases has submitted a proposal on urology common surgical perioperative management of antithrombotic drugs, the number of articles in view of the prostate surgery was too small, therefore, it is necessary to perform a meta-analysis of the existing studies.

The meta-analysis results of TURP with or without continuous use of antithrombotic drugs during the perioperative period showed that continuous use of antithrombotic drugs would increase the incidence of postoperative bleeding and increase the possibility of blood transfusion, and the discontinuation of antithrombotic drugs 5-10 days before surgery could reduce postoperative bleeding complications. However, there was no significant difference in the incidence of perioperative cardiovascular and cerebrovascular events between the persistent-usage group and discontinued group. Whether the application of perioperative drugs was continuous was not random except for the study by Nielsen *et al* ([@b16-etm-0-0-9102]), and it was determined according to the risk of patients\' cardiovascular and cerebrovascular events, which may reduce the incidence of perioperative cardiovascular and cerebrovascular events after drug withdrawal. In general, continuous use of antithrombotic drugs during the perioperative period of TURP will lead to more bleeding complications. For patients with low risk of thrombosis who take antithrombotic drugs for the prevention of cardiovascular and cerebrovascular diseases, it is recommended to stop using antithrombotic drugs preoperatively. In addition, some studies have found that the risk of thromboembolism is related to the operative time. The risk of thromboembolism increases with the length of surgery ([@b34-etm-0-0-9102],[@b35-etm-0-0-9102]). However, the included studies lacked relevant data, so large sample studies were expected to analyze the relationship between the risk of thromboembolism and the operative time.

In the meta-analysis of laser BPH surgery perioperative continuous and disable or unused antithrombotic drugs, there are three results showing the blood transfusion rate of the persistent-usage group was higher than that of the discontinued group. After analysis, the international normalized ratio (INR) of the prothrombin time of patients in the study of Bishop *et al* ([@b24-etm-0-0-9102]) is 2.61, while the average INR of the remaining studies is less than or equal to 2.0. Elzayat *et al* ([@b22-etm-0-0-9102]) found that high INR and early postoperative recovery of warfarin may be the main causes of blood transfusion, but the average blood transfusion volume in the above studies was not large (2.5 and 3.7 units). In addition, the results of transfusion rate and decreased intraoperative hemoglobin were inconsistent because the studies of transfusion rate were different from the studies included in decreased intraoperative hemoglobin. The results of this meta-analysis showed that the continuous use of drugs during the perioperative period of laser surgery did not increase decreased intraoperative hemoglobin and catheterization duration. Therefore, continuous preoperative anticoagulation is safe and feasible for BPH patients treated with laser surgery. In addition, some studies have found that blood transfusion rates in patients undergoing laser surgery were lower than that in TURP, suggesting that the risk of bleeding from laser surgery is lower than that in TURP ([@b36-etm-0-0-9102],[@b37-etm-0-0-9102]). This may be because the laser has a deeper solidification depth. The solidification depth of 2 µm laser is \~0.5-1.0 mm, while the solidification depth of TURP is \~0.29 mm ([@b38-etm-0-0-9102]).

It is also controversial whether heparin should be used during the discontinuation of antithrombotic drugs. Ong *et al* ([@b20-etm-0-0-9102]) believed that compared with the discontinuation of antithrombotic drugs, low molecular weight heparin replacement during the perioperative period of TURP would lead to higher postoperative bleeding complications (44 vs. 0%) and higher thrombotic complications (17 vs. 0%), while Dotan *et al* ([@b18-etm-0-0-9102]) considered that low molecular weight heparin replacement during TURP would only slightly extend the hospital stay and not lead to the increase of intraoperative and postoperative bleeding events. This meta-analysis found that in the laser BPH surgery perioperative period, there was no obvious difference in blood transfusion rate and catheterization duration between persistent-usage and heparin group, but heparin replacement promotes the drop in intraoperative hemoglobin, which reduced the value of low molecular weight heparin replacement in laser surgery. In general, the safety of low molecular weight heparin replacement in laser surgery is similar to that of traditional antithrombotic drugs, except for the effect on intraoperative hemoglobin. Therefore, we believe that low molecular weight heparin replacement should be avoided when it is not necessary. For patients at high risk of thrombosis, the surgeon may prescribe low molecular weight heparin in appropriate amounts.

As meta-analysis is an observational study, its results may be affected by bias, confounding and other factors. The limitations of this paper are as follows: i) Most of the included studies were based on the risk of cardiovascular and cerebrovascular disease in each patient to decide whether to stop antithrombotic drugs, resulting in our inability to analyze the risk of thrombosis after drug withdrawal; ii) Prostate volume, preoperative application of 5α reductase inhibitors, preoperative indwelling catheter have been shown to affect bleeding after prostate surgery, this meta-analysis did not consider these factors.

In conclusion, the discontinuation of antithrombotic drugs during the perioperative period of TURP can reduce the risk of postoperative bleeding; however, the risk of cardiovascular and cerebrovascular thrombosis and embolism after discontinuation should be carefully evaluated preoperatively. Continuous use of antithrombotic drugs during the perioperative period of laser BPH surgery is safe and feasible, and can be used as the preferred BPH surgical treatment for patients with high-risk cardiovascular and cerebrovascular diseases. There is controversy over the need for transitional treatment during the discontinuation of antithrombotic drugs. However, due to the limitations of the quality of the included studies, more high-quality studies are needed to verify the above conclusions.
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![Meta-analysis of the comparison between persistent-usage group and not taking group in TURP. The effect of persistent-usage and unused antithrombotic drugs on (A) incidence of postoperative bleeding and (B) blood transfusion rate was analyzed. TURP, transurethral resection of the prostate.](etm-20-04-3807-g02){#f3-etm-0-0-9102}
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###### 

Basic characteristics of the included studies.

                                                     Perioperative anticoagulation                                    
  -------------------------------------------------- ------------------------------- --------- ----- ---- ----- ----- -------
  Watson *et al*, 1990([@b13-etm-0-0-9102])          Aspirin                         TURP      5     \-   \-    34    a
  Thurston and Briant, 1993([@b14-etm-0-0-9102])     Aspirin                         TURP      14    \-   \-    111   a
  Ala-Opas and Grönlund, 1996([@b15-etm-0-0-9102])   Aspirin                         TURP      40    \-   \-    42    a
  Nielsen *et al*, 2000([@b16-etm-0-0-9102])         Aspirin                         TURP      26    \-   27    \-    b,e
  Wenders *et al*, 2012([@b17-etm-0-0-9102])         Aspirin                         TURP      42    \-   156   \-    a,b
  Dotan *et al*, 2002([@b18-etm-0-0-9102])           Anticoagulant drugs             TURP      20    \-   \-    20    b
  Taylor *et al*, 2011([@b19-etm-0-0-9102])          Anticoagulant drugs             TURP      7     \-   65    91    a,b,e
  Ong *et al*, 2015([@b20-etm-0-0-9102])             Antiplatelet drugs              TURP      32    \-   69    166   a,b,e
  Carmignani *et al*, 2014([@b21-etm-0-0-9102])      Antiplatelet drugs              ThuLEP    42    \-   \-    50    b
  Elzayat *et al*, 2006([@b22-etm-0-0-9102])         Anticoagulant drugs             HoLEP     14    34   33    \-    b
  Tyson and Lerner, 2009([@b23-etm-0-0-9102])        Anticoagulant drugs             HoLEP     38    \-   \-    37    d
  Bishop *et al*, 2013([@b24-etm-0-0-9102])          Anticoagulant drugs             HoLEP     52    \-   73    \-    b
  El Tayeb *et al*, 2016([@b25-etm-0-0-9102])        Anticoagulant drugs             HoLEP     30    \-   86    \-    b
  Sun *et al*, 2018([@b26-etm-0-0-9102])             Antiplatelet drugs              HoLEP     128   \-   41    955   b,c
  Ruszat *et al*, 2007([@b27-etm-0-0-9102])          Anticoagulant drugs             PVP       116   \-   \-    92    d
  Karatas *et al*, 2010([@b28-etm-0-0-9102])         Anticoagulant drugs             PVP       9     \-   58    \-    c,d
  Sohn *et al*, 2011([@b29-etm-0-0-9102])            Anticoagulant drugs             PVP       30    \-   30    \-    c
  Knapp *et al*, 2017([@b30-etm-0-0-9102])           Anticoagulant drugs             PVP       101   \-   \-    272   d
  Macchione *et al*, 2013([@b31-etm-0-0-9102])       Anticoagulant drugs             ThuVARP   41    35   \-    \-    b,c,d
  Sener *et al*, 2017([@b32-etm-0-0-9102])           Anticoagulant drugs             ThuVARP   56    47   \-    \-    b,c,d

a, Incidence of postoperative bleeding; b, blood transfusion rate; c, decreased intraoperative hemoglobin; d, catheterization duration; e, incidence of cardiovascular and cerebrovascular events.

###### 

NOS scores of the included studies.

  Authors year (ref.)                                           Selection   Comparability   Exposure   Total
  ------------------------------------------------------------- ----------- --------------- ---------- -------
  Watson *et al*, 1990([@b13-etm-0-0-9102])                     3           1               2          6
  Thurston and Briant, 1993([@b14-etm-0-0-9102])                3           2               2          7
  Ala-Opas and Grönlund 1996([@b15-etm-0-0-9102])               3           2               2          7
  Nielsen *et al*, 2000([@b16-etm-0-0-9102])                    2           1               1          4
  Wenders *et al*, 2012([@b17-etm-0-0-9102])                    4           2               2          8
  Dotan *et al*, 2002([@b18-etm-0-0-9102])                      4           2               2          8
  Taylor *et al*, 2011([@b19-etm-0-0-9102])                     3           1               2          6
  Ong *et al*, 2015([@b20-etm-0-0-9102])                        4           1               3          8
  Carmignani *et al*, 2014([@b21-etm-0-0-9102])                 4           1               2          7
  Elzayat *et al*, 2006([@b22-etm-0-0-9102])                    3           2               2          7
  Tyson and Lerner, 2009([@b23-etm-0-0-9102])                   4           2               2          8
  Bishop *et al*, 2013([@b24-etm-0-0-9102])                     3           2               2          7
  El Tayeb *et al*, 2016([@b25-etm-0-0-9102])                   4           1               2          7
  Sun *et al*, 2018([@b26-etm-0-0-9102])                        4           2               2          8
  Ruszat *et al*, 2007([@b27-etm-0-0-9102])                     4           2               2          8
  Karatas *et al*, 2010([@b28-etm-0-0-9102])                    3           1               2          6
  Sohn *et al*, 2011([@b29-etm-0-0-9102])                       4           1               2          7
  Knapp *et al*, 2017([@b30-etm-0-0-9102])                      4           2               3          9
  Macchione *et al*, 2013([@b31-etm-0-0-9102]) Sener *et al*,   3           1               2          6
  2017([@b32-etm-0-0-9102]) NOS, Newcastle Ottawa Scale.        4           2               3          9
